L. M. Lima de Araujo, Júlia Scarlet Batista Oliveira, Maria Vivyanne de Moura Lopes, Rafael Silva de Arruda, A. Oliveira, R. Martins
{"title":"Prevalence of proton pump inhibitors drug interactions in community pharmacy: a network analysis approach.","authors":"L. M. Lima de Araujo, Júlia Scarlet Batista Oliveira, Maria Vivyanne de Moura Lopes, Rafael Silva de Arruda, A. Oliveira, R. Martins","doi":"10.22563/2525-7323.2023.v8.n.2.p.15-22","DOIUrl":null,"url":null,"abstract":"Objective: The aim of this study is to identify the prevalence of drug interaction associated with proton pump inhibitors, associated factors and drugs involved. Methods: Cross-sectional study in 194 customers (> 18 years) of community pharmacies shortly after proton pump inhibitors acquisition (March 2019 to March 2020). Risk factors for drug interaction were assessed via multivariate logistic regression and relevance by network analysis. Results: The prevalence of drug interaction was 16.4% and was related to older age (OR=1.05; 95%CI 1.03 - 1.07) and female sex (OR=2.27; 95%CI 1, 15 - 4.47). The network analysis identified drug interaction involving omeprazole and pantoprazole as the most relevant and related to the prescription of levothyroxine, clopidogrel and cilostazol. Conclusion: The drug interaction among proton pump inhibitors users increase with age and are more common in women, especially those associated with levothyroxine, cilostazol and clopidogrel. ","PeriodicalId":110294,"journal":{"name":"JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA","volume":"42 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22563/2525-7323.2023.v8.n.2.p.15-22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: The aim of this study is to identify the prevalence of drug interaction associated with proton pump inhibitors, associated factors and drugs involved. Methods: Cross-sectional study in 194 customers (> 18 years) of community pharmacies shortly after proton pump inhibitors acquisition (March 2019 to March 2020). Risk factors for drug interaction were assessed via multivariate logistic regression and relevance by network analysis. Results: The prevalence of drug interaction was 16.4% and was related to older age (OR=1.05; 95%CI 1.03 - 1.07) and female sex (OR=2.27; 95%CI 1, 15 - 4.47). The network analysis identified drug interaction involving omeprazole and pantoprazole as the most relevant and related to the prescription of levothyroxine, clopidogrel and cilostazol. Conclusion: The drug interaction among proton pump inhibitors users increase with age and are more common in women, especially those associated with levothyroxine, cilostazol and clopidogrel.